Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01200238 · ClinicalTrials.gov registry record · Phase 2
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01200238 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 17 participants.
The verdict
NCT01200238, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
STA-9090, a synthetic small molecule, demonstrates significant activity for down-regulating Heat Shock Protein 90 or Hsp90 levels. Hsp90 belongs to a class of molecular chaperone proteins known to be critical regulators of cancer cell proliferation and survival. Preclinical laboratory experiments have shown STA-9090, an Hsp90 inhibitor, could inhibit ocular melanoma cell lines. The primary objective of this trial is to obtain evaluations of STA-9090 efficacy to metastatic ocular melanoma.
Interventions
- DRUG STA-9090
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-09-17 |
| Est. Completion | 2016-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01200238
The ClinicalTrials.gov registry entry for NCT01200238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STA-9090 is the first listed.
NCT01200238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01200238 about?
NCT01200238 is a clinical study titled "STA-9090(Ganetespib) in Metastatic Ocular Melanoma". STA-9090, a synthetic small molecule, demonstrates significant activity for down-regulating Heat Shock Protein 90 or Hsp90 levels. Hsp90 belongs to a class of molecular chaperone proteins known to be critical regulators of cancer cell proliferation and survival. Preclinical laboratory experiments ha...
What is the current status of trial NCT01200238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2010-09-17. Estimated completion is 2016-11-11.
What interventions are being tested in trial NCT01200238?
The interventions under investigation include: STA-9090 (DRUG).
Who is sponsoring clinical trial NCT01200238?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.